Michel Ducreux, ESMO 2019 – Treating advanced pancreatic cancer
We joined Michel Ducreux at ESMO 2019 to discuss the challenges and recent advances in treating pancreatic cancer.
1. What are the major challenges in the treatment of advanced pancreatic cancer? (00:04)
2. Why is it important to treat advanced pancreatic cancer faster? (00:30)
3. What have been the most important recent clinical advances in the treatment of advanced pancreatic cancer? (01:06)
4. What advances have been made in the development of biomarkers to inform treatment decisions? (01:56)
5. How important is genetic testing to personalise therapy in pancreatic cancer? (02:39)
Michel Ducreux has participated in advisory boards for Roche, Merck Serono, Amgen, Novartis, Sanofi, Bayer, Lilly, Servier, Ipsen, MSD. He has acted as a symposium speaker for Roche, Merck Serono, Novartis, Ipsen, Lilly, Amgen and Bayer. He has received research funding from Roche, Merck Serono and Keocyt; and has an immediate family member who has other relationships with Sandoz.
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Pancreatic Cancer
Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer
Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]
Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer
Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]
Marcus S Noel, ASCO GI22: Latest Advances in Pancreatic Cancer Treatment
touchONCOLOGY were thrilled to speak to Professor Marcus S Noel (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022. Questions What is the rationale for the use of L-asparaginase in the treatment of pancreatic cancer? 00:22-01:00 Could […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!